N-(naphthalen-1-ylmethyl)propan-2-amine | 14489-77-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(naphthalen-1-ylmethyl)propan-2-amine
• 英文别名: N-Isopropyl-1-naphthylmethylamin
• CAS: 14489-77-1
• 化学式: C₁₄H₁₇N
• mdl: MFCD06408148
• 分子量: 199.296
• InChiKey: LIMYPCKNYIHPHN-UHFFFAOYSA-N

物化性质

• 沸点：
  313.0±11.0 °C(Predicted)
• 密度：
  1.003±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-(naphthalen-1-ylmethyl)propan-2-amine 生成 N-(isopropyl)-N-(4'-t-butylbenzyl)-1-naphthylmethylamine
  参考文献：
  名称：

  ARAI, SEHJDZI;KAVAMOTO, NOBUO;UDA, MASANOBU;XIROSEH, SEHTSUKO;SEHKINO, TA+

  摘要：

  DOI：
• 作为产物：
  描述：

  1-naphthalen-1-yl-N-propan-2-ylmethanimine 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以96%的产率得到N-(naphthalen-1-ylmethyl)propan-2-amine
  参考文献：
  名称：

  N-手性氧化胺的催化不对称合成

  摘要：

  N-手性氧化胺的直接不对称合成是通过双金属钛催化剂完成的（高达91：9 er）。位于N立体中心的γ位置的羟基可通过三价胺底物的动态动力学拆分实现所需的N氧化。该方法进一步扩展到具有预先存在的立体中心的外消旋γ-氨基醇的动力学拆分，提供了一类重要的对映体富集的（高达99.9：0.1 er）构建基块，否则这些合成基团很难合成。

  DOI：

  10.1002/anie.201606354

文献信息

• Ruthenium-Catalyzed Transfer Hydrogenation of Nitriles: Reduction and Subsequent<i>N</i>-Monoalkylation to Secondary Amines
  作者：Svenja Werkmeister、Christoph Bornschein、Kathrin Junge、Matthias Beller

  DOI：10.1002/ejoc.201300151

  日期：2013.6

  The selective synthesis of amines continues to be of importance because of their application in the bulk and fine chemical industries. Herein, domino ruthenium-catalyzed transfer hydrogenation of nitriles with subsequent N-monoalkylation by using alcohols is described. With this novel approach, various nitriles were reductively N-monoalkylated in excellent yields.

  由于胺在大宗和精细化工行业中的应用，胺的选择性合成仍然很重要。本文描述了多米诺钌催化的腈转移氢化反应，随后使用醇进行 N-单烷基化反应。使用这种新方法，各种腈以极好的收率还原 N-单烷基化。
• THYROID RECEPTOR LIGANDS
  申请人：Ryono Denis E.

  公开号：US20100298276A1

  公开（公告）日：2010-11-25

  Thyroid receptor ligands are provided which have the general formula I wherein: R 1 is R 2 and R 3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R 2 and R 3 is other than hydrogen; R 4 is R 5 and R 6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl. R 7 is aryl, heteroaryl, alkyl, aralkyl, or heteroaralkyl; R 8 is aryl, heteroaryl, or cycloalkyl; R 9 is R 7 or hydrogen; R 10 is hydrogen, halogen, cyano or alkyl; R 11 and R 12 are each independently selected from the group consisting of hydrogen, halogen, alkoxy, hydroxy (—OH) cyano, and alkyl; R 13 is carboxylic acid (COOH) or esters thereof, phosphonic and phosphinic acid or esters thereof, sulfonic acid, tetrazole, hydroxamic acid, thiazolidinedione, acylsulfonamide, or other carboxylic acid surrogates known in the art; R 14 and R 15 may be the same or different and are selected from hydrogen and alkyl, or R 14 and R 15 may be joined together forming a chain of 2 to 5 methylene groups [—(CH2)m-, m=2, 3, 4 or 5], thus forming 3- to 6-membered cycloalkyl rings; R 16 is hydrogen or alkyl of 1 to 4 carbons; R 17 and R 18 are the same or different and selected from hydrogen, halogen and alkyl; n is 0 or an integer from 1 to 4; X is oxygen (—O—), sulfur (—S—), sulfonyl (—SO 2 —), sulfenyl (—SO—) selenium (—Se—), carbonyl (—CO—), amino (—NH—) or methylene (—CH2-); wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T 3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.

  提供了甲状腺受体配体，其具有一般公式I，其中：R1为R2和R3，R2和R3相同或不同，为氢、卤素、1至4个碳原子的烷基或3至5个碳原子的环烷基，但至少其中一个为非氢；R4为R5和R6，R5和R6相同或不同，选择自氢、芳基、杂环芳基、烷基、环烷基、芳基烷基或杂环芳基；R7为芳基、杂环芳基、烷基、芳基烷基或杂环芳基；R8为芳基、杂环芳基或环烷基；R9为R7或氢；R10为氢、卤素、氰基或烷基；R11和R12各自独立选择自氢、卤素、烷氧基、羟基（—OH）、氰基和烷基；R13为羧酸（COOH）或其酯、膦酸和膦酸酯、磺酸、四唑、羟胺酸、噻唑二酮、酰基磺胺或艺术中已知的其他羧酸替代物；R14和R15可相同或不同，选择自氢和烷基，或R14和R15可结合形成2至5个亚甲基组成的链[—(CH2)m-，m=2、3、4或5]，从而形成3至6成员的环烷基环；R16为氢或1至4个碳原子的烷基；R17和R18相同或不同，选择自氢、卤素和烷基；n为0或1至4的整数；X为氧（—O—）、硫（—S—）、砜基（—SO2—）、砜基（—SO—）、硒（—Se—）、羰基（—CO—）、氨基（—NH—）或亚甲基（—CH2-）；其中取代基如上述所述。此外，提供了一种方法，用于预防、抑制或治疗与代谢功能障碍或依赖于T3调节基因表达的疾病或障碍，其中上述化合物以治疗有效剂量给予。
• Zirconocene-Initiated Intramolecular Hydride Transfer in N-Iso­alkyl-Substituted Propargylamines
  作者：Ilfir Ramazanov、Rita Kadikova、Zukhra Saitova、Usein Dzhemilev

  DOI：10.1055/s-0037-1609336

  日期：2018.6

  unusual transformation of N-isoalkyl-substituted propargylamines into alkenylamines under the action of Cp2ZrCl2 and organoaluminum compounds (Me3Al, EtAlCl2) has been observed. The proposed mechanism, involving the N-isoalkyl-substituted propargylamine undergoing zirconocene-initiated intramolecular hydride transfer was supported by B3LYP/6-31G(d)/LanL2DZ calculations.

  已经观察到在 Cp2ZrCl2 和有机铝化合物（Me3Al、EtAlCl2）的作用下，N-异烷基取代的炔丙基胺异常转化为烯基胺。B3LYP/6-31G(d)/LanL2DZ 计算支持了所提出的机制，涉及 N-异烷基取代的炔丙胺进行二茂锆引发的分子内氢化物转移。
• THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS
  申请人：Fink M. David

  公开号：US20070004695A1

  公开（公告）日：2007-01-04

  The compounds are of the class thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives, useful as D 4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D 4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, Parkinsonism, Tardive Diskinesia, Gilles de la Tourette Syndrome, Conduct Disorder, and Oppositional Defiant Disorder. A further aspect of the invention is to provide a pharmaceutical composition, intermediates, and a method of making said class of compounds.

  这些化合物属于类别为噻唑异噁唑基和噻吩吡唑基苯氧基取代的丙基衍生物，可用作D4受体拮抗剂。这些化合物可用于治疗通过抑制D4受体介导的医疗状况。这些状况包括例如注意力缺陷多动障碍、强迫症、精神病、物质滥用、物质依赖、帕金森病、帕金森综合症、迟发性运动障碍、吉尔·德·拉·图雷特综合症、行为障碍和反抗行为障碍。发明的另一个方面是提供一种制药组合物、中间体和制备该类化合物的方法。
• TRIAZOLOTHIENOPYRIMIDINE COMPOUND INHIBITORS OF UREA TRANSPORTERS AND METHODS OF USING INHIBITORS
  申请人：Anderson Marc

  公开号：US20150057274A1

  公开（公告）日：2015-02-26

  Provided herein are small molecule triazolothienopyrimidine compounds that inhibit urea transport activity of solute transporters, particularly the UT-B transporter. The compounds described herein are useful for increasing solute clearance in states of fluid overload and for treating refractory edema associated with cardiovascular, renal, and metabolic diseases, disorders, and conditions.

  本文提供了一种小分子三唑噻吩嘧啶化合物，可抑制溶质转运体，特别是UT-B转运体的尿素转运活性。本文所描述的化合物可用于在液体过载状态下增加溶质清除，并用于治疗与心血管、肾脏和代谢性疾病、紊乱和情况相关的难治性水肿。